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Background: The ability to quantify the capacity of a central nervous system (CNS) drug to cross the human
blood-brain barrier (BBB) provides valuable information for de-risking drug development of new molecules. Here,
we present a study, where a suitable positron emission tomography (PET) ligand was not available for the evaluation
of a potent muscarinic acetylcholine receptor type-1 (M1) allosteric agonist (GSK1034702) in the primate and human
brain. Hence, direct radiolabelling of the novel molecule was performed and PET measurements were obtained and
combined with in vitro equilibrium dialysis assays to enable assessment of BBB transport and estimation of the free
brain concentration of GSK1034702 in vivo.
Methods: GSK1034702 was radiolabelled with 11C, and the brain distribution of [11C]GSK1034702 was investigated
in two anaesthetised baboons and four healthy male humans. In humans, PET scans were performed (following
intravenous injection of [11C]GSK1034702) at baseline and after a single oral 5-mg dose of GSK1034702. The in vitro
brain and plasma protein binding of GSK1034702 was determined across a range of species using equilibrium dialysis.
Results: The distribution of [11C]GSK1034702 in the primate brain was homogenous and the whole brain partition
coefficient (VT) was 3.97. In contrast, there was mild regional heterogeneity for GSK1034702 in the human brain.
Human whole brain VT estimates (4.9) were in broad agreement with primate VT and the fP/fND ratio (3.97 and 2.63,
respectively), consistent with transport by passive diffusion across the BBB.
Conclusion: In primate and human PET studies designed to evaluate the transport of a novel M1 allosteric agonist
(GSK1034702) across the BBB, we have demonstrated good brain uptake and BBB passage consistent with passive
diffusion or active influx. These studies discharged some of the perceived development risks for GSK1034702 and
provided information to progress the molecule into the next stage of clinical development.
Trial registration: Clinical trial details: ‘Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan
Study.’; clinicaltrial.gov identifier: NCT00937846.
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The main goal of early phase drug development is the
demonstration of substantial target engagement at doses
which are safe and tolerable and the determination of a
therapeutic dose range. Positron emission tomography
(PET) provides a unique technology for establishing the
relationship between the plasma concentration of a com-
pound and the degree of target engagement in tissues
such as the brain, which are not accessible by other
methods. The method of choice for defining this relation-
ship is the use of a well-understood probe (or radioligand)
which allows the quantification of target availability at
baseline and following the administration of various doses
of a novel drug. This approach allows the construction
of a realistic pharmacokinetic model relating the kin-
etics of a novel drug in blood and plasma to that in
tissue and enabling the prediction of target occupancy
in future clinical studies [1]. The practical limitation of
this approach is the requirement for a well-characterised
PET radioligand suitable for the quantification of the tar-
get examined. While a range of radioligands are available
for the central nervous system (CNS), a large number
of targets do not have a suitable radioligand. An al-
ternative, indirect, method to obtain target occupancy
information in these cases is to estimate the ‘free’ or
unbound concentration of the drug in the tissue of
interest (CFT) by directly labelling the drug molecule. The
total concentration of a drug in tissue is of limited utility,
as the non-specifically bound fraction is pharmacologically
inactive and thus the information is restricted to pro-
viding confidence in Blood-brain barrier (BBB) pene-
tration as a binary phenomenon. On the other hand,
CFT can be combined with an estimate of the affinity
of the drug for its target (KD), obtained from suitable
in vitro or pre-clinical studies, to obtain an estimate of tar-
get occupancy. While such an approach makes several
assumptions about the shape of the dose-occupancy re-
lationship and the equivalence between in vitro-derived
KD measures and the true in vivo KD, it provides a prac-
tical method for estimating target occupancy information
in the absence of a well-characterised PET radioligand.
The theory underpinning this approach has been fully
described in a recent manuscript [2]; hence, we present
a short summary only.
Passive transport of a drug across the BBB determines
that at equilibrium, the CFT (given by the product of the
total non-displaceable tissue concentration [CND] and its
free or unbound fraction [fND]) will be equal to the free
concentration of the drug in the plasma, CFP (=Cpfp)
which implies,
CND f ND ¼ Cp f p ð1ÞThe fractional occupancy of the target (OccT) can then
be calculated knowing Cpfp and KD as,
OCCT ¼
Cp f p
Cp f p þ KD
ð2Þ
The main goal of a ‘biodistribution’ PET study is thus
to test the assumption that the drug crosses the BBB
and to assess whether the transport is consistent with
passive diffusion. The distribution of a drug in the tissue
of interest can be evaluated following its labelling with a
radionuclide. The substitution of a 12C or 19 F atom by the
positron emitting isotopes 11C or 18 F enables the quantifi-
cation of the drug distribution in tissue over time, without
changing its physiochemical or pharmacological charac-
teristics. In principle, one can estimate the total volume of
distribution (VT [3]), for the drug in the brain, which is
equivalent to the equilibrium partition coefficient for the
drug between brain and plasma.
If the VT of a labelled drug is not reduced following
the administration of pharmacologically relevant dose of
the same drug, the total brain concentration of the drug
(CT) can be taken to measure the sum of the free and
the non-specifically bound components. In this case, the
VT will be independent of the dose of labelled com-
pound administered and measurements made at tracer
concentrations will provide an adequate estimate of drug
distribution at pharmacological doses.






It is worth noting that if the specific binding compo-
nent of a labelled drug is not negligible compared to the
free and non-displaceable components, the labelled drug
may be used as a radioligand to enable a direct examin-
ation of target occupancy.
While VT, CP, and fP can be measured directly in the
course of a PET study in humans, it is not possible to
measure fND directly, and hence, CFT cannot be ob-
tained without other information being available. If a
value for fND can be obtained, then the assumption of
passive diffusion across the BBB can be tested. Under
the conditions of passive diffusion, at equilibrium, CFT =
CFP, and Eq. 3 is simplified to:
VT ¼ f Pf ND
ð4Þ
A VT measurement from a PET biodistribution study
can be compared to the fP/fND ratio, and passive diffu-
sion can be assumed if the two are similar. Equilibrium
dialysis provides a practical method for measurements of
brain tissue fND (and also fP if necessary) [2].
We have applied the methodology above to examine the
distribution of GSK1034702 in the primate and human
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receptor allosteric agonist, which offers a potential ther-
apy for the treatment of cognitive dysfunction in neurode-
generative disorders. It belongs to the series of novel
N-substituted benzimidazolones recently described [4-6].
Muscarinic acetylcholine receptor (mAChR) agonists
such as xanomeline have produced some efficacy in
the treatment of cognitive dysfunction in patients with
Alzheimer's disease (AD) and schizophrenia (SZ) [7,8].
The therapeutic potential of the cholinergic agents tested
thus far (cholinesterase inhibitors and muscarinic ago-
nists) is modest and is thought to be limited by peripheral
m2AChR and/or m3AChR-related side effects, such as
gastrointestinal disturbances [9].
The discovery of an allosteric (or ectopic) site for
m1AChR that is not conserved across mAChR sub-
types has provided the opportunity to develop m1AChR
agonists with true receptor selectivity [10]. Allosteric
m1AChR selective agonists are postulated to display
reduced side effects, and thus greater utility, compared
with the existing non-selective orthosteric agonists. In an
initial study, in healthy smokers using the nicotine abstin-
ence model of cognitive dysfunction, GSK1034702 im-
proved episodic memory [6].
GSK1034702 [11] is a potent allosteric agonist at hu-
man recombinant m1AChR (pEC50 = 8.1 ± 0.1, intrinsic
activity (IA) = 0.78 ± 0.02) with 100-fold selectivity over
human m2-5AChR receptors and with >90 over other
molecular targets from a variety of classes. GSK1034702
is a weak substrate for P-glycoprotein (PGP) (efflux ratio
of 2.6:1 in MDCK cell line expressing human MDR1)
and has displayed some species variability in brain-to-
plasma ratios (brain/blood ratios of 0.4, 0.6 and 2.0:1, in
mouse, rat and marmoset, respectively; GlaxoSmithKline
(GSK) data on file). Therefore, the delivery of GSK1034702
into human brain could have been adversely affected.
Initially, the primate study was carried out in order to
demonstrate that [11C]GSK1034702 crossed the BBB in
primates, before proceeding to expensive human studies.
The human study aimed to use PET with radioactively la-
belled GSK1034702 to help ascertain the role PGP plays in
limiting brain penetration in the presence and absence of a
pharmacological relevant oral non-labelled dose of 5 mg.
Here, we investigated the distribution of GSK1034702 in
the living human brain. These data provide vital information
to determine whether GSK1034702 can be used at doses
that offer therapeutic benefit to patients with AD and SZ
without inducing intolerable muscarinic-related side effects.
Methods
Radiosynthesis of [11C]GSK1034702
[11C]GSK1034702 was prepared as described previously
[5] via a palladium-catalysed cross coupling reaction be-
tween GSK1804165A and [11C]CH3I (Figure 1).Evaluation of [11C]GSK1034702 kinetics in the Papio
anubis brain
Study design
The brain distribution of carbon-11-labelled GSK1034702
([11C]GSK1034702) was conducted in two anaesthetised
baboons (P. anubis), to assess its transport across the BBB.
These studies were conducted at Columbia University
Medical Center, New York. The study was approved by
the Columbia University Institutional Animal Care and
Use Committee (IACUC).
Two adult baboons were studied over a 6-week period.
Subject A (an ovariectomised female) received two injec-
tions of [11C]GSK1034702 22 days apart, while subject
B (male) received a single injection of [11C]GSK1034702.
Each experimental session included a single dynamic
PET scan.
Data acquisition
Fasted animals were immobilised with intramuscular
ketamine injection (10 mg/kg), and anesthetised with
1.8% isoflurane via an endotracheal tube. Vital signs
were monitored every 10 min and the temperature was
kept constant at 37°C with heated water blankets. An
intravenous (IV) perfusion line was used for hydration
and injection of the radiotracer. A catheter was inserted
in a femoral artery for arterial blood sampling. The head
was positioned at the centre of the field of view. PET im-
aging was performed with the ECAT EXACT HR+ PET
scanner (Siemens/CTI, Knoxville, TN) operating in 3D
mode (in-plane resolution of 4.3, 4.5, 5.4 and 8.0 mm, full
width at half maximum (FWHM) at a distance of 0, 1, 10
and 20 cm from the centre of the field of view) [12]. A 15-
min transmission scan was obtained prior to radiotracer
injection for attenuation correction. The injected mass
and radioactivity had an upper limit of 1.16 μg and
47 MBq, respectively. Following IV administration (45-s
bolus) of a single dose of [11C]GSK1034702 dynamic
PET, arterial blood and metabolite data were acquired
for 120 min (subject A) for the first two scans and
only 60 min for the third scan due to a technical issue
(subject B).
Image processing and quantification of binding parameters
Regions of interest (ROIs) were drawn on previously ac-
quired T1-weighted anatomical magnetic resonance im-
aging (MRI) brain images for each animal. The following
regions were defined: cerebellum, hippocampus, thalamus,
striatum, frontal cortex and occipital cortex. Regions were
drawn in the MEDx (Sensor Systems Inc., Sterling, VA,
USA) software environment. PET emission data were
attenuation-corrected using the transmission scan, and
frames were reconstructed using a Shepp filter (cutoff
0.5 cycles/projection rays). Decay-corrected PET images


















Figure 1 Synthesis route for [11C]GSK1034702.
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gional boundaries were transferred from the MRI to the
individual registered PET frames, and time-activity curves
were measured in the MEDx environment. Right and left
regions were averaged. For a given animal, the same re-
gions were used for all scans.
For all non-human primate studies, the non-protein-
bound fraction of [11C]GSK1034702 in arterial plasma
(fP) was quantified using the following methodology:
triplicate 200 μL aliquots of plasma collected before in-
jection were mixed with [11C]GSK1034702, pipetted into
ultrafiltration units (Centrifree; Amicon, Danvers, MA,
USA) and centrifuged at room temperature (20 min at
4,000 rpm). At the end of centrifugation, plasma and ul-
trafiltrate activities were counted and fP was calculated as
the ratio of ultrafiltrate to total activity concentrations.
Brain time activity curves (TACs) were corrected for the
contribution of blood activity assuming a 5% blood vol-
ume. A metabolite-corrected arterial input function and
regional TACs were fitted to a compartmental model to
derive regional VT estimates as well as a whole brain VT.
Evaluation of [11C]GSK1034702 kinetics in the human
brain
Study design
An open-label PET study (GSK study number 110771) was
conducted to assess the transport of [11C]GSK1034702
across the BBB and its distribution in the living hu-
man brain. Four healthy males aged between 35 and
55 years old, with body mass index (BMI) between 19.0
and 29.0 kg/m2, and the absence of past or present neuro-
logical, medical or psychiatric illnesses and concomitant
medications were enrolled. Clinical status was assessed by
history, physical examination, routine blood tests, urine
toxicology and electrocardiogram. All subjects provided
written informed consent. The study was approved by the
Edinburgh Independent Ethics Committee for Medical
Research and permission to administer radioisotopes
was obtained from the Administration of Radioactive
Substances Advisory Committee of the UK. Subjects were
recruited by and monitored by the Hammersmith Medicines
Research (HMR) clinic. All scanning procedures wereperformed at the GlaxoSmithKline Clinical Imaging Center,
Hammersmith Hospital, London.
Each subject underwent a single study day, during which
PET imaging was performed. T1-weighted structural MRI
scan was performed for all subjects to provide neuroana-
tomical information. A tracer dose of [11C]GSK1034702
(mass <50 μg) was administered as an IV bolus im-
mediately before each PET scan. During the scanning
day, each subject received a baseline [11C]GSK1034702
scan, followed by a single 5-mg oral dose (p.o.) of
GSK10347012 and a subsequent [11C]GSK1034702 scan
approximately 4 h post-dose. Subjects returned to the
clinic for a follow-up visit 7 to 14 days following the
oral dose of GSK1034702.
Data acquisition
Dynamic PET data were acquired using a Siemens
Biograph 6 Truepoint with TrueV PET-CT (Siemens
Healthcare, Malvern, PA, USA) in three-dimensional
(3D) mode. A computed tomography (CT) scan was ac-
quired for attenuation correction of PET data prior to ad-
ministration of the radiotracer. A cannula was inserted
under local anaesthesia into the radial artery, contralateral
to the tracer injection site, and used to collect arterial
blood samples to estimate the time course of radioactivity
and metabolism of GSK1034702. The radiotracer was
administered as an IV bolus over 20 s, and dynamic PET
data were acquired for 90 min. The injected mass of
GSK1034702 did not exceed 50 μg.
Arterial blood radioactivity was measured continu-
ously for the first 15 min after [11C]GSK1034702 injec-
tion, using a continuous sampling system (ABSS Allogg,
Mariefred, Sweden). In addition, 12 serial discrete blood
samples were obtained (at 5, 10, 15, 20, 25, 30, 40, 50, 60,
70, 80 and 90 min post injection), to determine whole
blood and plasma activity. Seven samples (at 5, 10, 20, 30,
50, 70 and 90 min) were further processed by HPLC to
measure the fraction of plasma activity representing
unmetabolised GSK1034702. For all human studies, the
non-protein-bound fraction of [11C]GSK1034702 in arter-
ial plasma (fP) was assessed by ultrafiltration for the blood
sample taken at the beginning of the scan.







Cerebellum 4.07 3.79 3.09
Hippocampus 4.78 4.62 3.52
Thalamus 4.06 3.91 2.75
Striatum 3.86 3.95 3.21
Frontal Ctx 3.92 3.73 3.52
Occipital Ctx 4.49 4.64 3.89
Whole brain 4.20 4.19 3.52
VT = volume of distribution (mL.cm
−3).
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sequence: TR = 3,000 ms, TE = 3.66 ms, flip angle = 9°, voxel
size = 1 mm3, 208 slices) were acquired on a 3 T Tim Trio
MRI scanner system (Siemens Healthcare) to provide a
T1-weighted image for co-registration with their PET data.
Serial venous blood samples were obtained at 0, 1, 2, 3,
4 and 5.5 h after the administration of a single oral dose of
5 mg of GSK1034702, to estimate the time course of
GSK1034702 plasma concentration. Plasma samples were
analysed using a validated analytical method.
Image processing and quantification of binding parameters
Emission PET data were binned into 26 frames (dura-
tions: 8 × 15 s, 3 × 60 s, 5 × 2 min, 5 ×min, 5 × 10 min)
and reconstructed using Fourier re-binning and a two-
dimensional (2D) filtered back projection algorithm with
a ramp filter [13]. Image data were then smoothed with
a Gaussian filter (5 mm FWHM). The PET reconstruc-
tion process included corrections for scatter, randoms
and attenuation [13]. Dynamic PET data were corrected
for motion via frame-to-frame image registration and
aligned with the structural T1 MRI image using SPM5
(Wellcome Trust Centre for Neuroimaging, http://www.fil.
ion.ucl.ac.uk/spm) with a mutual information cost function.
The CIC Neuroanatomical Atlas [14] was non-linearly
deformed into the individual's space to obtain a persona-
lised anatomical parcellation of ROIs. These ROIs were
applied to the dynamic emission data, and regional TACs
were obtained for the whole brain, frontal cortex, occipital
cortex, striatum, thalamus, hippocampus and cerebellum.
In addition, as some degree of regional heterogeneity
was observed in the binding of [11C]GSK1034702 in the
human brain, a regular-sized rectangle (432 mm3) was
manually placed over the area of highest signal in the
medial temporal lobe (MTL), centred in the hippocampus
for each subject and applied to the dynamic emission data
to generate a MTLTAC. See Additional file 1: Figure S1A,
for further methological details of ROI definition.
Regional TACs with an arterial plasma metabolite-
corrected input function were fitted using compartmen-
tal analyses, and estimates of the delivery rate constant
for transfer from arterial plasma to tissue (K1) and VT
were obtained. VT estimates derived were compared to
in vitro estimates derived from equilibrium dialysis to in-
vestigate the BBB transport process.
The kinetic parameters from the PET studies were ap-
plied to the pharmacokinetic (PK) data from the individual
subjects in order to estimate the regional distribution of
GSK103702 following an oral dose.
Brain and plasma protein binding of GSK1034702
The in vitro brain and plasma protein binding of GSK1034702
across a range of species was determined using equilib-
rium dialysis as described previously [2].Results and discussion
Evaluation of [11C]GSK1034702 CNS penetration and
kinetics in the P. anubis brain
Summary scan data
The injected dose of [11C]GSK1034702 was 27.7 ± 17.7 MBq
(with these and subsequent values expressed as mean ±
standard deviation [SD]), with the average injected mass
of 1.05 ± 0.05 μg. The free fraction of [11C]GSK1034702 in
plasma (fP) was 0.54 ± 0.21.
Quantification of PET data
A two-tissue compartmental model was identified as the
most appropriate kinetic model based on parsimony cri-
teria and was used to derive regional VT values. The distri-
bution of [11C]GSK1034702 was homogenous throughout
the brain, with regional VT values of similar magnitude
(see Table 1 and associated K1 values are reported in
Additional file 2: Table S1A), suggesting that any specific
binding component of [11C]GSK1034702 is small com-
pared to the ‘free and non-specific’ binding component.
The whole brain VT for [
11C]GSK1034702 in the P. anubis
brain was 3.97 ± 0.38. There was high uptake in the pituit-
ary which is situated outside the BBB.
Evaluation of [11C]GSK1034702 CNS penetration and
kinetics in the human brain
Summary scan data
A total of four male subjects, with a mean (±SD) age of
43.5 ± 5.1 years and a mean (±SD) BMI of 26.6 ± 2.9 kg/m2,
were enrolled into the study. In all, five technically adequate
data sets were obtained in three subjects (three baseline
scans and two scans following the administration of oral
GSK1034702). The post-dose scan for subject 1 was not
performed due to the failure of [11C]GSK1034702 synthesis,
while the acquisition of arterial blood data for both scans
of subject 3 was compromised by problems with a blood
sampling device, and hence, a quantitative tracer kinetic
analysis of the scans from this subject was not performed.
The mean (±SD) injected dose of [11C]GSK1034702 was
308 ± 26 MBq, with a mean (±SD) injected GSK1034702
mass of 42.9 ± 5.2 μg.
Figure 2 Parent fraction of [11C]GSK1034702 over the time
course of the PET scan for all subjects (N = 4). Error bars denote
the Standard Deviation of the [11C]GSK1034702 parent fraction.
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tolerated. One subject experienced two mild and transient
adverse events during this study (salivary hypersecretion
and dysgeusia). Both adverse events were considered to be
drug-related. No serious adverse events were observed.
The plasma concentration of GSK1034702 following the
administration of 5 mg p.o, and the measured free fraction
in the plasma are presented in Table 2.
Quantification of PET data
[11C]GSK1034702 underwent minimal metabolism over
the time course of the PET scan during both the baseline
and the post-dose sessions (Figure 2). Following the ad-
ministration of oral GSK10347012, the plasma concen-
tration reached peak levels by the time of the post-dose
scan in all subjects and remained relatively constant over
the course of the PET scan (Figure 3). The plasma con-
centrations achieved were consistent with the prediction
based on the First-Time-In-Human safety and tolerabil-
ity study (GSK study number 110623 and study number
NCT00743405 on CT.gov).
The regional brain TACs for all scans analysed are pre-
sented in Figure 4 and distribution by a representative
subjects integral image in Figure 5. A two-tissue compart-
mental model was identified as the most appropriate kin-
etic model based on parsimony criteria, which employed
the Akaike information criteria [15] for model selection,
and was used to derive regional VT values (Table 2).
As opposed to the non-human primate data, there ap-
peared to be some regional heterogeneity in the distribution
of [11C]GSK1034702, with the VT in the MTL in the range
of 7-13, while that in the white matter being in the range of
4-5. The whole brain VT in humans was 4.9. We did not
expect to see displaceable [11C]GSK1034702 binding, and
hence did not expect a change in binding following the ad-
ministration of an oral dose of 5 mg GSK1034702. As ex-
pected, we saw no significant change in either VT or K1 for
[11C]GSK1034702, however, there was a non-significant
reduction in the MTL area in both subjects where follow-
ing administration of 5 mg of GSK1034702 (see Table 3
and Figures 4 and 5).Table 2 GSK1034702 plasma concentration at start of PET sca
Time between oral dose of GSK1034702 and








The dose for all subjects was 5 mg of GSK1034702. Time given is the time in hours
GSK1034702 PK concentrations were taken between results from the start of the sc
fractions were measured from plasma samples acquired from the four subjects duriBrain kinetics of GSK1034702 in the human brain
The kinetic parameters derived from the two-tissue kin-
etic model were applied to the plasma pharmacokinetic
data from individual subjects in order to estimate the re-
gional pharmacological GSK1034702 concentration time
course following an oral dose. These data predict a peak
brain concentration only slightly later than that in the
plasma, indicative of a rapid exchange of GSK1034702
across the BBB (see Figure 6 for illustrative results from
subject 4).
Estimation of GSK1034702 transport across the BBB
The in vitro plasma protein and brain tissue binding of
GSK1034702 were determined in mouse, rat, dog, mar-
moset, monkey and human tissue by equilibrium dialysis.
The bound fractions in plasma and brain were similar in
all species tested (Table 4).
The in vitro equilibrium dialysis fP values for the mon-
key and human plasma (0.58 and 0.44, respectively) were
consistent with the values obtained by ultrafiltration in
the course of the PET studies in baboon and humann and GSK1034702 plasma free fraction (fP)
fP
1034702 plasma concentration







post oral dose of GSK1034702 at which the PET scan acquisition started.
an are taken between 4 and 50 min before the PET scan. In vivo plasma-free
ng each PET scan. fP = plasma-free fraction.
Figure 3 Clinical Study plasma concentration of GSK1034702
over time (in h). Subjects were scanned between 3 and 5 h after a
single oral dose of GSK1034702. Figure 3 shows that PK levels of
GSK1034702 had reached a peak in all subjects prior to the
acquisition of the PET data.
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brain fND (=0.17) data was used for both human and ba-
boon estimation.
The fP/fND ratios derived from the equilibrium dialysis
estimates indicated that if GSK1034702 crosses the BBB
by passive diffusion, the expected VT would be 3.4 and 2.6
in the primate and human brain, respectively. The VT
measured in the primate and human cortex (4.0 and 4.9)
is in broad agreement with a passive diffusion model.
Discussion
The exploding costs of drug development, and in par-
ticular in the neurosciences, make it imperative that de-
cisions about compound progression are made as early
as possible, in order to terminate unsuitable candidates
before they reach later, more expensive phases of devel-
opment. The fundamental requirement of any new mol-
ecule is that it is able to reach its site of action in
pharmacologically meaningful quantities, at doses which
are generally safe and tolerable. The quantification of
target engagement in the CNS is hampered by our in-
ability to directly assay the target in the living human
brain and the frequent species differences encountered.
The direct quantification of drug interaction with its tar-
get via the use of PET with a selective radioligand is the
method of choice in deriving the relationship between
the plasma concentration of a compound and the occu-
pancy of its target. This technique can provide information
on target occupancy following single-dose administration
that can be extrapolated to provide accurate estimates of
occupancy in the clinically meaningful setting of repeat-
dose administration [1].A large fraction of CNS targets of interest are not suit-
able for examination by this method, due to the lack of
suitable radioligands. In such situations, the traditional
approach has been to label the molecule of interest and
derive the partition coefficient between the labelled drug
in plasma and in the brain, as a semi-quantitative meas-
ure of drug availability at the target. Such measures are
useful, but more limited than direct estimates of target
occupancy, since the partition coefficient (known in the
PET literature as the total volume of distribution, VT)
provides quantification of the total concentration of the
drug in the brain. The total concentration is composed
of the drug specifically bound to the target (VS) and the
non-displaceably bound drug (VND), which comprises
drug-bound non-specifically as well as the free drug. If the
VS can be estimated robustly from kinetic data, direct tar-
get engagement may be evaluated, using the methods
developed for target-specific radioligands. However, this
situation is rare for drugs in development, primarily due
to the presence of high levels of non-specific binding (high
VND). Hence, for a large proportion of labelled drugs, the
measured VT is essentially equivalent to VND.
The pharmacologically relevant fraction of the drug is
the free concentration, CFT, which is able to interact with
the target, and the fND is needed to estimate CFT when
only the total tissue concentration is available. If the
drug transport across the BBB is by passive diffusion, then
at equilibrium, the free concentration of the drug in
plasma would be equal to CFT. A demonstration that the
VT for a compound is approximated by the ratio fP/fND
provides confidence in drug transport by passive diffusion
and hence the estimation of CFT from peripheral plasma
data.
We did not see conclusive evidence for a change in re-
gional VT values for GSK103702 following a pharmaco-
logical dose that was statistically significant, suggesting
that any specific binding component of [11C]GSK1034702
is negligible compared to the free and non-specific com-
ponents. The whole brain VT in human was 4.9, which is
broadly comparable to the measured fP/fND of 2.63, imply-
ing passive diffusion across the BBB. The difference be-
tween VT and fP/fND is most likely due to experimental
noise in the PET and equilibrium dialysis assays, but even
if this difference represents a deviation from passive diffu-
sion across the BBB, this deviation would be in the direc-
tion of an active transport of the molecule into the brain.
Such a situation, were it to be clinically relevant would
lead to a higher brain CFT than the plasma-free concentra-
tion, and thus would minimise the incidence of peripheral
side effects for a given central m1AChR occupancy.
Similarly, there was significant uptake of GSK1034702
into the brain at tracer quantities and following oral dos-
ing of 5 mg in the human study. As there was some re-
gional heterogeneity in the binding of GSK1034702 in
Figure 4 Regional time activity curves of [11C]GSK1034702 in the human brain and model fits. Regions of interest: white circle, MTL =medial
temporal lobe; x, cerebellum; white square, thalamus; diamond, cortex = sum of cortical regions including both cortical grey and white matter; plus sign,
WM= all cerebral white matter. Solid lines are two tissue compartmental model fits. For each subject, a regular-sized rectangle (432 mm3) was manually
placed over the area of highest signal in the medial temporal lobe (MTL), centred in the hippocampus; this is presented in the data as the MTL ROI.
Ridler et al. EJNMMI Research 2014, 4:66 Page 8 of 12
http://www.ejnmmires.com/content/4/1/66
Figure 5 [11C]GSK1034702 in Subject 4 in the human brain. Tracer [11C]GSK1034702 PET data - integral images 0-120 min in subject 4. Post
dose 5 mg of GSK1034702 [11C]GSK1034702 PET data - integral images 0-120 min in subject 4. K1 = rate constant for transfer from arterial plasma
to tissue (mL.cm−3.min−1). VT = volume of distribution (mL.cm
−3). Regions of interest: MTL =medial temporal lobe (ROI defined above), cerebellum,
thalamus and striatum and cortex = sum of cortical regions (includes grey and white matter); white matter = all cerebral white matter.
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http://www.ejnmmires.com/content/4/1/66the human brain, the cortex was used to derive a VT as-
sumed to be the most representative of the VND, as this
region produced VT in the lower range of those exam-
ined. The whole brain VT was 4.9, which is in broad agree-
ment with primate VT and the fP/fND ratio (3.97 and 2.63,
respectively).
The results are broadly consistent across species, al-
though the primate and human estimates are somewhat
higher than the fP/fND ratio. Thus, if active transportplays a role in the BBB passage of GSK1034702, it would
appear to be an active influx into the brain (leading to
VT > fP/fND), rather than an extrusion of the compound
from the brain (which would lead to VT < fP/fND). Thus,
if anything, therapeutic levels of m1AChR occupancy
may be achieved with even lower plasma concentrations
and hence lower incidence of adverse events, than those
in the passive diffusion scenario. The presence of an
active transport mechanism would make extrapolation
Table 3 Regional VT, K1 values and GSK1034702 injected mass (μg) and [
11C]GSK1034702 injected dose in MBq for
each scan in the human brain
ROI Subject 1 Subject 2 Subject 4
Scan 1 (baseline) Scan 1 (baseline) Scan 2 (post dose) Scan 1(baseline) Scan 2 (post dose)
K1 VT K1 VT K1 VT K1 VT K1 VT
MTL 0.33 7.81 0.19 13.3 0.16 8.30 0.24 7.11 0.25 6.91
Cerebellum 0.23 5.33 0.19 4.75 0.15 3.69 0.19 5.17 0.19 4.56
White matter 0.13 4.63 0.10 4.38 0.08 4.01 0.11 5.04 0.11 4.49
Cortex 0.19 5.37 0.16 5.00 0.12 4.03 0.16 5.57 0.17 4.81
Striatum 0.20 5.59 0.16 5.05 0.13 5.29 0.18 5.83 0.18 4.93
Thalamus 0.29 6.29 0.19 5.44 0.15 4.39 0.20 5.74 0.20 5.11
GSK1034702 injected mass 38.48 34.17 49.35 46.02 44.19
[11C]GSK1034702 injected dose 284.19 322.12 263.02 300.50 325.50
Regions of interest: MTL =medial temporal lobe (ROI defined above), cerebellum, thalamus and striatum and cortex = sum of cortical regions (includes grey and
white matter); white matter = all cerebral white matter. K1 = rate constant for transfer from arterial plasma to tissue (mL.cm
−3.min−1). VT = volume of distribution
(mL.cm−3). GSK1034702 injected mass in microgrammes. [11C]GSK1034702 injected dose in megabecquerel.
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lematic, due to possible changes in the transport kinetics
at higher doses (e.g. due to saturation of the trans-
porters). However, we do not think that this is an issue for
GSK1034702, as our examination of a therapeutically rele-
vant dose (5 mg p.o.) produced results similar to those atFigure 6 Predicted time course of GSK1034702 concentration in the
Regions of interest: MTL =medial temporal lobe (defined above), WM = all
and white matter), plasma = the measured plasma concentration of GSK103tracer dose. The inclusion of a therapeutic dose requires
extra safety information and complicates the study design,
but may be worth including in situations where active
transport is suspected.
A regionally heterogeneous distribution of [11C]GSK1034702
was observed in humans, with the highest VT observed inhuman brain following a single 5-mg oral dose in subject 4.
cerebral white matter, cortex = sum of cortical regions (including grey
4702 for comparison.
Table 4 In vitro plasma protein binding and brain tissue binding of GSK1034702
Species Plasma protein binding (%) fP Brain tissue binding (%) fND
Mouse 48.2 (±1.2) 0.52 86.7 (±0.6) 0.13
Rat (CD) 47.2 (±1.4) 0.53 87.7 (±0.5) 0.12
Rat (LH) 45.5 (±1.5) 0.55 84.9 (±1.0) 0.15
Dog 44.5 (±3.6) 0.56 81.8 (±1.8) 0.18
Monkey 41.7 (±2.7) 0.58 83.2 (±1.1) 0.17
Human 55.8 (±3.6) 0.44 N/A
Plasma protein binding and brain tissue binding of GSK1034702 evaluated by equilibrium dialysis over 5 h at concentration of 1 μg/mL. Values represent mean ±
standard deviation from n = 6 determinations, fP = plasma-free fraction, fND = brain-free fraction. CD = Sprague Dawley rat and LH = Lister hooded rat.
Ridler et al. EJNMMI Research 2014, 4:66 Page 11 of 12
http://www.ejnmmires.com/content/4/1/66the medial temporal lobe (MTL), consistent with the known
distribution of m1AChR in the human brain [16]. This
finding is supported by a small (but non-significant) re-
duction in the MTL VT following the administration of a
5-mg oral dose of GSK1034702, in both subjects for
whom pre- and post-dose data was available. Our data are
consistent with a small specific binding component for
[11C]GSK1034702 in the human brain. The data from
humans are in contrast to those in the baboon brain,
where homogenous distribution was observed. A poten-
tial explanation for the between species differences in dis-
tribution could be a masking of high affinity states of
m1AChR by ketamine [17,18] in the baboon brain. How-
ever, further studies would be needed to properly under-
stand these differences.
The magnitude of the specific component may be too
low for [11C]GSK1034702 to be a useful PET ligand for
the m1AChR. This may be due either to a relatively low
in vivo affinity of [11C]GSK1034702 for the m1AChR in
relation to the target density or due to a relatively low spe-
cific activity (SA) and hence a high mass of GSK1034702,
leading to partial blockade of the specific binding compo-
nent being used in this study. The radiolabelling method
used precludes the achievement of higher SA than re-
ported here, and hence, [11C]GSK1034702 may not be
suitable for the quantification of m1AChR density with
PET. However, it may provide a useful lead in the search
for related compounds with higher affinity for this target
or compounds that may be labelled using methods leading
to higher SA.
This study type has several limitations. For the PET
data, the presence of brain-penetrant metabolites cannot
be ruled out for all compounds using these methods. In
this case, it is unlikely because there was little metabolism
of the compound and because the data was well described
by a two-tissue compartment model. For the equilibrium
dialysis data, the duration of dialysis, temperature and buf-
fer conditions and the fact that different primate brains
were used for the in vitro and in vivo data of the primate
study, as well as primate brain instead of human brain tis-
sue for the human study, could all introduce errors into
the measurements.Conclusions
In primate and human PET studies designed to evaluate
the transport across the BBB of a novel selective M1 re-
ceptor allosteric agonist GSK1034702, we have demon-
strated good brain uptake. Although there was variability
in this limited dataset, BBB kinetics were consistent with
passive diffusion or active influx.
The single oral dose of 5 mg GSK1034702 was well
tolerated by healthy subjects in this PET study, and the
pharmacokinetic parameters were consistent with those
observed in a separate First-Time-In-Human safety and
tolerability study (GSK study number 110623 and study
number NCT00743405 on CT.gov).
In conclusion, an examination of the BBB kinetics of
GSK1034702 in phase 0 and phase I of development has
discharged some of the perceived development risks for
GSK1034702 and provided information to progress the
molecule into the next stage of clinical development.Additional files
Additional file 1: Figure S1A. Methods definition for hand drawn
region of interest.
Additional file 2: Table S1A. Supplementary table showing Regional
K1 Values in Papio Anubis Brain.Abbreviations
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